Related Experiment Video

Updated: Feb 13, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K

Entresto, a New Panacea for Heart Failure?

Peter Khalil1, Ghazal Kabbach1, Sarmad Said2

  • 1Department of Internal Medicine, Texas Tech University Health Sciences Center, Paul L. Foster School of Medicine, El Paso, TX, United States.

Cardiovascular & Hematological Agents in Medicinal Chemistry
|March 14, 2018
PubMed

Insights

Entresto (Sacubitril/Valsartan) offers a new treatment for heart failure with reduced ejection fraction (HFrEF), improving patient outcomes. This review details its development and clinical impact.

Area of Science:

  • Cardiology
  • Pharmacology
  • Drug Development

Background:

  • Heart Failure (HF) poses a significant global health challenge.
  • Current HF management includes beta blockers, diuretics, ACE inhibitors, and ARBs.
  • Previous therapies have limitations in fully addressing HF pathophysiology.

Purpose of the Study:

  • To review the development of Sacubitril/Valsartan (Entresto).
  • To discuss the limitations of prior heart failure medications.
  • To examine Entresto's mechanism, clinical trials, and future indications.

Main Methods:

  • Review of historical data and clinical trial outcomes.
  • Analysis of pharmacological mechanisms of action.
  • Examination of regulatory approval processes.

Main Results:

  • Entresto, an angiotensin receptor neprilysin inhibitor, is FDA-approved for HFrEF.
  • It combines angiotensin receptor blockade (valsartan) and neprilysin inhibition (sacubitril).
  • Represents a significant advancement in HF pharmacotherapy.

Conclusions:

  • Entresto offers a novel therapeutic approach for HFrEF.
  • Understanding its development provides insights into HF treatment evolution.
  • Ongoing trials explore expanded uses for Entresto in cardiovascular medicine.

Keywords:
Heart failureangiotensin receptor blockersangiotensin receptor neprilysin inhibitorangiotensin-converting enzyme inhibitorsheart failure with preserved ejection fractionheart failure with reduced ejection fraction.

More Related Videos

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.2K
Gene Transfer for Ischemic Heart Failure in a Preclinical Model07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.4K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
958
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
399
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
363